CSBR — Q3 2026 Financial Report Analysis

A note on the period label: this analysis covers the three months ended July 31, 2026, which Champions Oncology itself calls fiscal first quarter of fiscal 2027. The company's fiscal year ends April 30, so its fiscal labels run ahead of the calendar. It is filed here under calendar Q3 2026 (the quarter in which the period ended). Source: Form 10-Q filed with the SEC on September 11, 2026.

Overview: better economics on every dollar of revenue, all of it spent on growth

Champions Oncology (Nasdaq: CSBR) is a research-services company, not a drug developer. Its core asset is the TumorGraft Platform — a bank of "patient-derived xenograft" (PDX) models, which are real human tumors implanted into immune-deficient mice so that a drug can be tested against actual human cancer tissue before it ever reaches a patient. Pharmaceutical and biotech companies pay Champions to run those studies. A second, much smaller business sells data rather than lab work: licensed access to the genomic and response data generated from that model bank.

In the quarter ended July 31, 2026, revenue rose 8.8% to $15.2 million. The more interesting line is directly beneath it: the cost of delivering that revenue went down 5.8%, to $7.5 million. Serving more customers for less money lifted gross margin — the share of revenue left after the direct cost of doing the work, before overhead — from 42.9% to 50.5%, and added $1.7 million of gross profit.

None of that reached the bottom line. Operating expenses rose $1.6 million over the same period, and the operating loss finished at $409,000 versus $527,000 a year earlier. Net loss was $426,000, or $(0.03) per share, effectively unchanged.

The numbers

Figures from the Unaudited Condensed Consolidated Statements of Operations and Cash Flows in the Form 10-Q. Gross profit and gross margin are calculated as revenue less cost of oncology revenue; Champions does not present a gross profit subtotal itself.

Where the growth came from — and where it didn't

Champions breaks revenue into three pieces. They moved in three different directions:

Pharmacology services — the mouse-model studies — is still essentially the whole company. Management attributes the 7.0% increase to "increased sales and improved conversion rates, with a greater proportion of contracted work converting to revenue." That phrasing matters: part of the gain is not new demand but faster execution against work Champions had already signed, which is a throughput improvement rather than a booking improvement.

Data licensing nearly tripled off a small base, adding $582,000. Management describes "increased commercial activity around our data offerings" and "a growing pipeline of opportunities." This is the line to watch, because it is structurally different from the rest of the business: selling access to data the company already owns carries very little incremental cost, whereas running a study consumes mice, reagents and lab time. A dollar of license revenue is worth considerably more than a dollar of study revenue. Even so, at $893,000 it is under 6% of the total — meaningful to the margin, not yet to the top line. Note also that license revenue is recognized at a single point in time when data access is delivered, so this line will be lumpy quarter to quarter rather than smoothly recurring.

Other TOS revenue (flow cytometry services and the Lumin bioinformatics software subscription) fell almost 60%. This is a deliberate retreat, not a loss of business Champions was fighting for: the filing states these offerings "are not part of the Company's current strategic focus" and that the decline reflects the company "shifting its strategic focus and investment away from these areas." Strip this managed run-off out and the remaining business grew 11.2%, not 8.8% — worth knowing, because the drag is finite and nearly exhausted at $183,000.

The margin improvement is real, and partly borrowed

Cost of revenue falling in absolute terms while revenue grows is unusual and deserves a specific explanation. The filing gives one: the decrease was "primarily attributable to lower outsourced laboratory service costs, including radiolabeling work performed by third-party laboratories, partially offset by higher royalty costs associated with the increase in revenue."

Two things are bundled there, pulling opposite ways:

• Less outsourcing is the favorable half — work that used to be sent to third-party labs (radiolabeling in particular, a specialized technique for tracking a compound through the body) is either being done in-house or simply wasn't required by this quarter's mix of studies. If it is mix, some of it reverses when a radiolabel-heavy study comes through; if it is insourcing, it sticks.
• Royalties are the unfavorable half, and they are scaling fast. Champions licenses tumor samples from third parties to build into PDX models, and owes royalties of 2% to 20% of contract price when those licensed models are used in a sale. Royalty expense was $226,000 this quarter against $39,000 a year ago — a $187,000 increase, nearly six times the prior-year figure, against revenue growth of 8.8%. That is a cost growing far faster than the revenue it rides on, and it is a structural claim on future gross margin as more of the sellable model bank comes from licensed rather than owned material.

So: a 7.6-point margin gain, of which the durable portion is smaller than the headline. Treat the 50%-plus gross margin as a new high-water mark to be defended rather than a new floor.

Operating expenses: a commercial build-out and an accounting artifact

The $1.6 million increase in operating expense has two very different components.

Sales and marketing rose 66.6%, to $3.09 million from $1.86 million — the single largest swing in the income statement. Management attributes it to "higher compensation expense associated with the expansion of the Company's commercial organization, including personnel supporting both the Company's core research services business and its data licensing initiatives," and says plainly that the expense "is expected to remain elevated." Sales and marketing went from 13.3% of revenue to 20.3%. That is a deliberate bet: hire the sales force now, collect the revenue later. It is also the reason the operating loss barely improved despite a $1.7 million gross profit gain. The honest read is that this quarter's result tells you very little about whether the bet works — the cost is fully in the numbers and essentially none of the intended benefit is.

Research and development rose 12.6% to $2.34 million — but the underlying spend actually fell. The filing attributes the increase to "higher share-based compensation expense related to Corellia, our wholly owned subsidiary focused on target discovery." Corellia stock-option expense inside R&D was $438,000 this quarter versus $30,000 a year ago. Back that out and R&D was $1.91 million versus $2.05 million — a 7.1% decrease. The component detail confirms it: laboratory supplies fell to $352,000 from $637,000 and outside services to $324,000 from $448,000, while compensation rose $440,000, almost all of it the non-cash option charge. Anyone reading "R&D up 12.6%" as increased research intensity would have it backwards; real research inputs were cut.

General and administrative rose only 4.0% to $2.67 million, on higher executive compensation following leadership changes made in the second quarter of fiscal 2026, partly offset by lower IT infrastructure costs.

The non-cash distortion, stated plainly

Total stock-based compensation was $766,000 this quarter versus $208,000 a year ago — a $558,000 increase, most of it the Corellia grants. Stock compensation is a real economic cost to shareholders, but it does not consume cash. Excluding it entirely, Champions ran an operating profit of roughly $357,000 this quarter against an operating loss of roughly $319,000 a year ago — a swing of about $676,000, versus the $118,000 improvement the GAAP line shows. The cash-expense business improved roughly five times more than the reported operating loss suggests.

One structural detail on the Corellia options: because they are issued by the subsidiary and remain unexercised, the offsetting credit is recorded as non-controlling interest (which rose from $129,000 to $567,000) rather than as additional paid-in capital, and no portion of the company's loss is attributed to it. They are not yet dilutive to CSBR common shareholders — but they represent a claim on Corellia specifically, meaning any future value created by the target-discovery subsidiary will not accrue entirely to CSBR holders.

Balance sheet: the constraint on everything above

This is where the quarter gets uncomfortable.

*Unbilled services comparative is as of May 1, 2025, as presented in the filing.

Cash is $4.4 million, down from $10.3 million a year ago. Working capital — current assets minus the bills due within a year — is $563,000. For a company with a $15 million quarterly cost base, that is a very thin cushion. Management states it believes cash on hand plus expected operating cash flow is adequate to fund operations "through at least September 2027," which is the company's own twelve-month assertion and carries no going-concern qualification.

Operating cash flow was negative $492,000, against positive $600,000 a year ago. The filing says this "was primarily driven by the net loss for the quarter." That explanation does not survive the arithmetic. The net loss was $426,000, but non-cash add-backs — $766,000 of stock compensation, $314,000 of depreciation, $268,000 of lease amortization — more than covered it, leaving roughly $929,000 of cash generation before working capital. The cash actually went out the door through a $1.43 million reduction in accounts payable (from $6.9 million to $5.6 million), partly offset by a $724,000 build in deferred revenue. In other words, the quarter's cash use is a payables paydown, not operating underperformance. That distinction matters: a payables unwind is a one-time normalization, whereas the prior-year comparison flatters itself for the opposite reason — last year's positive $600,000 was largely a $1.76 million receivables collection, not operating generation either.

Two balance-sheet items worth flagging:

• Unbilled services have grown 52% year over year, from $5.4 million to $8.2 million, while billed receivables were roughly flat. Unbilled services are revenue Champions has earned by doing the work but has not yet invoiced, because invoicing is tied to contract milestones rather than to progress. This is normal in contract research, but the growth rate is well ahead of the 8.8% revenue growth, and it means a widening gap between when work is performed and when cash arrives. For a company with $4.4 million of cash, the trajectory of this line is as important as the income statement.
• Deferred revenue rose to $9.55 million from $8.83 million, with $7.5 million of new customer prepayments added against $6.8 million recognized. Deferred revenue is money collected in advance for work not yet done — a forward order book that has already been paid for. A growing balance is a modestly positive signal on near-term demand.

An eleven-year lease commitment

Total assets jumped from $27.0 million to $33.3 million and total liabilities from $22.9 million to $28.8 million in a single quarter. Almost all of that is one transaction: in June 2026 Champions amended the lease on its Rockville, Maryland laboratory — its primary operating facility — extending expiration from February 2029 to March 2037, and recognized an additional $6.3 million right-of-use asset and matching lease liability. Non-current operating lease liabilities went from $3.0 million to $9.9 million.

This is not new borrowing and it does not affect cash this quarter. It is, however, a company with $4.4 million of cash and $563,000 of working capital committing to an additional eight years of its main facility. Read charitably, it is a capacity decision consistent with the commercial build-out — you do not sign to 2037 if you expect to shrink. Read cautiously, it removes flexibility that a business at this cash level might want to keep. Separately, the Hackensack, New Jersey corporate headquarters lease expires in November 2026, a near-term item the filing does not address further.

Takeaway: Champions delivered the best gross margin comparison in years — 50.5% versus 42.9%, with cost of revenue falling in absolute dollars — and then spent every cent of the $1.7 million gain on a 67% increase in sales and marketing headcount. Whether this quarter was good or bad is therefore not yet answerable from this quarter: the cost of the commercial expansion is fully reflected and the revenue it is meant to produce is not. What is answerable is the constraint. With $4.4 million of cash, $563,000 of working capital, unbilled receivables growing 52% year over year, and an eleven-year lease just signed, Champions has bought itself a growth push it can afford only if the sales investment converts within a few quarters rather than a few years.

Outlook

Champions issued no numeric guidance in this filing — as a smaller reporting company it does not publish revenue or earnings forecasts in its 10-Q. Management's forward-looking statements are limited to three:

1. Sales and marketing expense "is expected to remain elevated" as the company continues investing in commercial capability. The ~$3.1 million quarterly run rate should be treated as the new base, not a spike.
2. A "growing pipeline of opportunities" in data licensing as commercial efforts and customer engagement expand.
3. Liquidity is adequate "through at least September 2027" on cash on hand plus expected operating cash flow.

Our read on the trajectory. The operating model is working better than the reported loss indicates: excluding stock compensation, the business generated roughly $357,000 of operating profit versus a $319,000 loss a year ago, and gross margin crossed 50% for the first time in recent memory. The problem is timing, not direction. The sales expansion adds roughly $1.2 million per quarter of cost; at the current 50.5% gross margin, it needs to generate about $2.4 million of incremental quarterly revenue — around 16% growth on this quarter's base — simply to pay for itself. Nothing in this filing indicates that has begun.

That leaves three things to watch in the October 31, 2026 quarter. First, whether data license revenue holds near $900,000 or reverts toward the $300,000 level, which will show whether the near-tripling was a genuine commercial ramp or the point-in-time recognition of one or two large contracts landing in a single quarter. Second, whether gross margin holds above 50% as royalty expense keeps compounding — $226,000 against $39,000 is the fastest-growing cost in the company. Third, and most important, whether operating cash flow returns to positive now that the payables normalization is behind it. With $4.4 million of cash and a commercial build-out already committed to, Champions has roughly two to three quarters of visible room to show that the sales investment converts. If it does, the margin structure now in place makes this a meaningfully more profitable company than it was a year ago. If it does not, the financing conversation arrives before the growth does.